A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This study is a phase Ib add-on study of the combination of LDE255 to azacitidine in patients
without marrow response after at least 6 cycles of azacitidine.